Constanze Ulmer-Eilfort
Director/Board Member bij EVOTEC SE
Actieve functies van Constanze Ulmer-Eilfort
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
EVOTEC SE | Director/Board Member | 01-06-2021 | - |
AFFIMED N.V. | Director/Board Member | 21-06-2023 | - |
Independent Dir/Board Member | 21-06-2023 | - | |
Peters, Schönberger & Partner GbR
Peters, Schönberger & Partner GbR Miscellaneous Commercial ServicesCommercial Services Peters, Schönberger & Partner is a Munich-based law firm that provides legal advice and data protection services. The German company specializes in auditing and creating annual financial statements, representing clients in state courts and arbitration, and providing practical and interdisciplinary support to foundations, non-profit organizations, and other charitable institutions. The firm also offers investment office services for large assets, as well as neutral assessment, arbitration, and consulting services for businesses. Peters, Schönberger & Partner is a competent partner for medium-sized and international companies, private equity firms, and NPOs. The company also provides advice and support on tax compliance management and GoBD. | Corporate Officer/Principal | 01-01-2022 | - |
Proxygen Co.
Proxygen Co. Investment ManagersFinance Proxygen Co. is an American biotech company focused on the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. Proxygen's headquarters and laboratory operations are based in an undisclosed location, and the private company employs talent both locally and remotely all over. The company maintains strategic partnerships with Merck & Co, Boehringer Ingelheim, and Merck KGaA to co-create synergies along the drug development pipeline. | Director/Board Member | 01-01-2022 | - |
Loopbaan van Constanze Ulmer-Eilfort
Eerdere bekende functies van Constanze Ulmer-Eilfort
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Baker Mckenzie LLP | Corporate Officer/Principal | 01-01-2000 | 01-01-2021 |
Opleiding van Constanze Ulmer-Eilfort
University of Pennsylvania | Graduate Degree |
Freie Universität Berlin | Doctorate Degree |
Ludwig-Maximilians-Universität München | Graduate Degree |
Statistieken
Internationaal
Duitsland | 6 |
Verenigde Staten | 3 |
Italië | 2 |
Operationeel
Director/Board Member | 3 |
Graduate Degree | 2 |
Corporate Officer/Principal | 2 |
Sectoraal
Consumer Services | 4 |
Health Technology | 3 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
AFFIMED N.V. | Health Technology |
EVOTEC SE | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Peters, Schönberger & Partner GbR
Peters, Schönberger & Partner GbR Miscellaneous Commercial ServicesCommercial Services Peters, Schönberger & Partner is a Munich-based law firm that provides legal advice and data protection services. The German company specializes in auditing and creating annual financial statements, representing clients in state courts and arbitration, and providing practical and interdisciplinary support to foundations, non-profit organizations, and other charitable institutions. The firm also offers investment office services for large assets, as well as neutral assessment, arbitration, and consulting services for businesses. Peters, Schönberger & Partner is a competent partner for medium-sized and international companies, private equity firms, and NPOs. The company also provides advice and support on tax compliance management and GoBD. | Commercial Services |
Proxygen Co.
Proxygen Co. Investment ManagersFinance Proxygen Co. is an American biotech company focused on the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. Proxygen's headquarters and laboratory operations are based in an undisclosed location, and the private company employs talent both locally and remotely all over. The company maintains strategic partnerships with Merck & Co, Boehringer Ingelheim, and Merck KGaA to co-create synergies along the drug development pipeline. | Finance |
Baker Mckenzie LLP |